Naureen Starling
Royal Marsden NHS Foundation Trust · The Royal Marsden NHSFT UK
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Naureen Starling as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:54 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07903571 · Cohort Study to eLucidAte Causes, Behaviour and Outcomes of gastRo Intestinal Tract Cancers in the YoungRoyal Marsden NHS Foundation Trust · not yet recruiting · Colorectal Cancer, Gastro-oesophageal Adenocarcinoma, Hepato-Biliary Carcinoma in Situ Nos · principal investigator
- Ph2NCT06250036 · Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric CancerRoyal Marsden NHS Foundation Trust · suspended · Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer · principal investigator
- N/ANCT02112357 · Feasibility of a Molecular Characterisation Approach to TreatmentRoyal Marsden NHS Foundation Trust · unknown · Advanced Gastrointestinal Cancers · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:54 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med · 20081,820 citationsRCR 44.3
- Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.Cancer Discov · 2018190 citationsRCR 5.6
- 136 citationsRCR 3.7
- 106 citationsRCR 5.1
- Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.Ann Oncol · 201692 citationsRCR 3.2
- 91 citationsRCR 2.2
- 63 citationsRCR 1.9
- 60 citationsRCR 1.4
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.Br J Cancer · 200848 citationsRCR 1.1
- Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.Clin Chem · 201845 citationsRCR 1.3